Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Study finds higher death rate in calorie-restricted models of IBD

In a surprising result, Michigan State University researchers looking at the effects of diet on bowel disease found that mice on a calorie-restricted diet were more likely to die after being infected with an inflammation-causing bacterial pathogen in the colon.

21 Mar 2012

Positive data from Aerpio's AKB-9778 Phase 1 trial on DME

Aerpio Therapeutics, a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease, today announced positive data from its Phase 1 trial of AKB-9778 for the treatment of diabetic macular edema.

21 Mar 2012

Jennerex initiates JX-594 plus irinotecan Phase 1/2 trial in metastatic colorectal cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.

20 Mar 2012

New information on efficacy of CLA in treating Crohn's disease

The Nutritional Immunology and Molecular Medicine Laboratory (NIMML) research team at Virginia Tech has discovered important new information on the efficacy of conjugated linoleic acid (CLA) in treating Crohn's disease, a form of inflammatory bowel disease (IBD). CLA is a naturally occurring acid found in meat and dairy products known for its anti-cancer and immune modulatory properties.

20 Mar 2012

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.

19 Mar 2012

Positive data from VBL Therapeutics' VB-201 Phase 2 study on psoriasis, atherosclerosis

VBL Therapeutics, a clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that a Phase 2 sub-study of VB-201 in moderate to severe psoriasis patients with cardiovascular risk has successfully achieved its primary endpoint demonstrating a statistically significant reduction in vascular inflammation associated with atherosclerotic lesions as measured by PET-CT imaging.

17 Mar 2012

Experts highlight latest advances in use of biomarkers in various diseases

Over the last few decades there has been an explosion in the discovery of biomarkers for diagnosis, disease monitoring, and prognostic evaluation. In the April issue of Translational Research, entitled "Biomarkers: New Tools of Modern Medicine," an international group of medical experts explores the promise and challenges of biomarker discovery and highlights the latest advances in the use of biomarkers in various diseases.

16 Mar 2012

OHRI, uOttawa to lead first stem cell therapy trial for septic shock

A team of researchers from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) has been awarded $367,000 from the Canadian Institutes of Health Research (CIHR) and $75,000 from the Stem Cell Network to lead the first clinical trial in the world of a stem cell therapy for septic shock.

16 Mar 2012

Study identifies 190 proteins crucial to the functions of key immune sensors

In a healthy immune system, invading pathogens trigger a cascade of alerts and responses to fight off the infection. Sensors called toll-like receptors, or TLRs, act as one of the first lines of defense. Two of these sensors, known as TLR7 and TLR9, specifically recognize and respond to microbial RNA and DNA, respectively. But what determines how these TLRs get where they need to be and sound the alarm for pathogen infection?

15 Mar 2012

Scientists discover cells that chaperone food antigens in the intestine

With every meal, immune cells in the intestine stand like sentries at a citadel, turning away harmful bacteria but allowing vitamins and nutrients to pass. Now, researchers at Washington University School of Medicine in St. Louis have identified the cells that chaperone food antigens, or proteins, in the intestine so that the immune system doesn't mount an attack.

15 Mar 2012

Researchers discover how Salmonella thrives in the digestive tract

UC Irvine researchers have discovered how Salmonella, a bacterium found in contaminated raw foods that causes major gastrointestinal distress in humans, thrives in the digestive tract despite the immune system's best efforts to destroy it.

15 Mar 2012

Many children with Crohn's disease and IBD benefit from ImproveCareNow

Many children with Crohn's disease and ulcerative colitis who received treatment through ImproveCareNow, a national quality improvement and research network, ceased to have symptoms and no longer needed to take steroids for disease management.

13 Mar 2012

Five new genetic mutations linked with Crohn's disease in Ashkenazi Jews

In the largest study of its kind, researchers from Mount Sinai School of Medicine have discovered five new genetic mutations associated with Crohn's disease in Jews of Eastern European descent, also known as Ashkenazi Jews.

9 Mar 2012

Dr. Falk Pharma, Lipid Therapeutics enter license agreement for LT-02 to treat UC

Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced that they have entered into a licensing agreement for the European rights to Lipid Therapeutics' lead product, LT-02, for ulcerative colitis.

8 Mar 2012

BioLineRx receives European patent for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a European patent has been granted claiming BL-1020's composition and its use for the treatment of schizophrenia.

8 Mar 2012

Colon cancer screening guidelines released

According to a new guidance statement from the American College of Physicians all adults should get screened for colon cancer once they get older to reduce their risk of dying from the nation's number two cancer killer.

7 Mar 2012

BioLineRx granted Israeli approval for BL-7040 Phase II clinical trial for IBD

BioLineRx a biopharmaceutical development company, announced today that it has received approval from the Israeli Ministry of Health for commencing a Phase II clinical trial of BL-7040, an orally available molecule for treating Inflammatory Bowel Disease (IBD).

5 Mar 2012

Gastroenterologists provide five facts to reduce colon cancer risk

The number two cancer killer in the U.S. is often preventable and highly curable. "It's important for people to understand that, with proper screening, colon cancer can not only be detected early, but often can be prevented from developing," says Dr. Felice Schnoll-Sussman, a gastroenterologist and acting director of The Jay Monahan Center for Gastrointestinal Health at NewYork-Presbyterian/Weill Cornell Medical Center.

2 Mar 2012

Pediatricians should screen all children for vitamin D deficiency

As study after study shows the fundamental role vitamin D plays in disease and health, vitamin D deficiency — which often develops insidiously in childhood — should be on every parent's and pediatrician's radar, say physicians from the Johns Hopkins Children's Center.

23 Feb 2012

NYSDOH approves Enzo Biochem's ColonSentry test

Enzo Biochem, Inc. today announced that the New York State Department of Health has approved Enzo Clinical Labs' use of the ColonSentry test for providing an assessment of a patient's risk of having colorectal cancer.

22 Feb 2012